Get the Daily Brief
Latest Biotech News
Inflammasome protein ASC rewires pancreatic cancer metabolism
A Nature Communications study identified the inflammasome adaptor protein ASC as a central regulator linking innate immune signaling to mitochondrial metabolism in pancreatic cancer. Authors Chey,...
Succinate receptor SUCNR1 restrains hematopoiesis and limits AML
A Nature Communications paper showed that succinate receptor 1 (SUCNR1) functions as a metabolic sentinel that limits blood cell formation and suppresses acute myeloid leukemia progression. The...
Ferritin‑scaffold MERS spike vaccine shows potent responses
Researchers reported a stabilized MERS‑CoV spike protein presented on a ferritin nanoparticle induced robust immune responses in preclinical studies. The stabilized spike nanoparticle vaccine...
Dual targeting of viral and host pathways yields synergistic COVID activity
An Acta Pharmaceutica Sinica B study identified small‑molecule inhibitors of SARS‑CoV‑2 papain‑like protease (PLpro) and host kinase RIPK1 that, when combined, produced potent synergistic...
Bispecific siRNAs silence two oncogenic nodes at once
Nitto Denko reported a bispecific siRNA design that simultaneously knocks down YAP1 and WWTR1 (TAZ), two Hippo‑pathway effectors implicated in cancer. The Molecular Therapy — Nucleic Acids paper...
Eikon, Agomab pull $350M in IPOs — aftermarket punishes debut stocks
BioCentury reported that Eikon and Agomab raised $350 million combined in recent IPOs but saw share prices decline in the aftermarket. The public‑equity roundup highlighted uneven demand for...
Hims halts compounded Wegovy amid federal pressure
Hims & Hers stopped offering a compounded version of Novo Nordisk’s Wegovy after escalating legal pressure from federal regulators and calls for criminal review. The company said it “decided to...
PLpro and RIPK1 inhibitors synergize against SARS‑CoV‑2 in mice
Researchers reported that combining inhibitors targeting SARS‑CoV‑2 papain‑like protease (PLpro) with host RIPK1 inhibitors produced potent, synergistic antiviral effects in a mouse COVID‑19...
Brepocitinib clears proof‑of‑concept — Roivant advances to pivotal testing
A proof‑of‑concept study showed brepocitinib, a dual JAK1/TYK2 inhibitor licensed by Priovant (a Roivant subsidiary) from Pfizer, met endpoints in cutaneous sarcoidosis, a rare inflammatory skin...
Sanofi dissects failed tolebrutinib PPMS study — company retreats
Sanofi disclosed data from a failed Phase 3 trial of the BTK inhibitor tolebrutinib in primary progressive multiple sclerosis (PPMS), an outcome that prompted the company to step back from the...
ARPA‑H trims commercialization staff amid restructure
ARPA‑H cut staff tied to commercialization and operations, according to multiple sources, shedding roles meant to move funded technologies toward market. The agency confirmed layoffs but said...
Biotech markets thaw: IPOs lift nearly $1bn as Series A steadies
Four drug companies went public this week—Agomab, Eikon, Spyglass and Veradermics—raising about $350m on IPO days and approaching nearly $1bn combined in recent public offerings, according to...
CRISPR strategy exploits oncogene amplification to target tumors
Researchers at Spain’s CNIO and CIEMAT described a gene‑editing approach that selectively targets tumors with oncogene amplifications using CRISPR‑Cas9 vulnerabilities tied to genomic overload....
AI‑native pharma scales clinical development; Insilico hires oncology lead
Formation Bio described an AI‑native model that prioritizes clinical development workflows to speed and derisk drug programs; CTO Dan Neil outlined the hub‑and‑spoke asset structure and...
Rice secures ARPA‑H PRINT funding to bioprint kidney tissue
Rice University won up to $24.8 million over five years from ARPA‑H to develop bioprinted kidney tissues under the PRINT program, aiming to address the organ shortage by advancing engineered renal...
Guideline issues: therapeutic drug monitoring recommended for IBD biologics
A multidisciplinary panel released evidence‑based guidelines endorsing therapeutic drug monitoring (TDM) for biologic therapies in inflammatory bowel disease. The guideline synthesizes trial and...
Hims halts compounded Wegovy pill: regulator, industry pressure forces retreat
Hims announced it will stop offering a compounded version of Novo Nordisk’s Wegovy following legal threats and regulatory scrutiny. The telehealth company said it “decided to stop offering access”...
Bayer unveils Phase 3 win: asundexian cuts secondary stroke risk
Bayer reported Phase 3 data showing its Factor XIa inhibitor asundexian reduced the risk of secondary stroke by 26% without increasing bleeding, presenting asundexian as a potential oral...
Adaptive projects MRD boom: ClonoSeq poised for rapid revenue growth
Adaptive Biotechnologies raised its 2026 outlook on the back of accelerating adoption of its ClonoSeq minimal residual disease (MRD) assay, guiding MRD revenue to $255–$265 million and projecting...
UniQure pauses mid, high doses in Fabry gene trial after liver toxicity
UniQure said it paused mid‑ and high‑dose cohorts in its Fabry disease gene therapy study after two patients who received 4x10^13 gc/kg experienced grade 3 liver enzyme elevations. The safety...